|Download Diagnostics 2009: Moving towards personalised medicine (910kb)|
The fabric of the in vitro diagnostics (IVD) industry is changing. New names are appearing at the top and some emerging specialists are being valued more than some traditional big names: Siemens and Inverness entered the ranks of the top ten by sales after a flurry of deals in 2006-2007, and the women’s healthcare specialist, Hologic, increased its value through key combinations in 2007-2008.
In its new report, Diagnostics 2009: Moving towards personalised medicine, PwC reviews deal activity in the in vitro diagnostics (IVD) sector and significant events for personalised medicine, a field which is fast rising to prominence in healthcare innovation.
The topics covered include M&A and licensing deal activity, regulatory developments on biomarker testing, partnerships with the pharmaceutical industry, significant events beyond deal activity, case studies and key drivers of future revenue growth for personalised medicine diagnostics.